What Finceramica does

Finceramica Faenza S.p.A. is an Italy-based, privately-held medical device company founded in 1987 and headquartered in Faenza, operating as part of the Tampieri group. The company develops, manufactures, and markets proprietary biomimetic hydroxyapatite-based bioceramic materials for bone and joint regeneration across cranial, orthopedic, maxillo-facial, and spinal surgical applications.

Its core product platform comprises five device families: CustomBone Service (custom-made porous hydroxyapatite cranial implants designed from patient CT scans via the CustomBone Web Portal), MaioRegen (tri-layered collagen-hydroxyapatite-magnesium osteochondral scaffold offered in Prime, Slim, and Chondro+ configurations), SINTlife (magnesium-substituted hydroxyapatite resorbable bone substitute in putty form), ENGIpore (pre-formed porous hydroxyapatite bone substitute), and RegenOss (collagen-hydroxyapatite composite patches and strips). Cumulative clinical evidence includes 9,500+ CustomBone implants with a 92.3% success rate and 7,000+ MaioRegen patients treated.

Finceramica generates revenue through direct sales of one-time medical devices to hospitals and surgical centers via enterprise field sales, the CustomBone Web Portal, and the MyFin restricted professional portal, with pricing negotiated case-by-case. The go-to-market is built around surgeon-targeted clinical evidence, medical congress presence (ICRS, EUROSPINE, EANS, SINch, UniKnee), surgical skills sponsorship, and the CustomBone Web Portal workflow for custom implant ordering and 3D design approval. The company is EU MDR-certified and serves a global customer base with an 11-50 employee footprint.

Name

Finceramica

Legal name

Fin-ceramica Faenza S.p.A.

Website

https://finceramica.it

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

11–50 employees

Short description

Finceramica Faenza S.p.A. is an Italy-based medical device company that develops and sells biomimetic hydroxyapatite-based implants and scaffolds for cranial, orthopedic, spinal, and maxillo-facial regenerative surgery, serving neurosurgeons, orthopedic surgeons, and hospitals globally through direct enterprise sales.

Ownership category

akta.pro rank

Product category

Orthopedic and Cranial Biomaterial Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD), 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• Bone regeneration devices
• Cranial implant manufacturing
• Osteochondral scaffold products
• Medical biomaterial devices
• Orthopedic surgical implants

Headquarters

HQ city

Faenza

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Custom-made medical implants and bone regeneration devices: Finceramica generates revenue through the sale of proprietary medical devices for bone and joint regeneration. Product lines include CustomBone Service (custom cranial implants), MaioRegen (osteochondral scaffolds), SINTlife (bone substitutes), ENGIpore (pre-formed bone substitutes), and RegenOss (collagen-hydroxyapatite composites). These are sold directly to hospitals and surgeons, with revenue being project-based and procedure-driven rather than subscription-based.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Finceramica manufactures and markets innovative therapeutic solutions for the biomedical sector, focused on bone and joint regeneration. Its portfolio includes custom-made 3D porous hydroxyapatite cranial implants, tri-layered collagen-hydroxyapatite osteochondral scaffolds, magnesium-substituted hydroxyapatite bone substitutes, porous hydroxyapatite bone grafts, and collagen-hydroxyapatite composite biomaterials used by neurosurgeons, orthopedic surgeons, and maxillofacial surgeons. Products are designed for cranioplasty, spinal fusion, and joint reconstruction procedures.

Product overview

Finceramica is a medical device company specializing in advanced regenerative surgery solutions for bone and joint regeneration. The product portfolio centers on five core biomaterial platforms: CustomBone Service (custom-made hydroxyapatite cranial implants), MaioRegen (multi-layered osteochondral scaffold with three configurations: Prime, Slim, and Chondro+), ENGIpore (pre-formed porous hydroxyapatite bone substitute), SINTlife (magnesium-substituted hydroxyapatite putty), and RegenOss (collagen-hydroxyapatite composite). These products serve neuro, orthopedic, and spinal surgery applications across skull, shoulder, spine, knee, and other skeletal areas. The CustomBone Web Portal supports the ordering and design workflow for custom cranial implants.

Differentiator

Problem solved

Functional benefit

Brands

• CustomBone Service: Custom-made cranial implant service using hydroxyapatite for cranioplasty procedures
• MaioRegen
• SINTlife
• RegenOss
• ENGIpore

Products and services

• CustomBone Service

Quantifiable outcome

• 92.3% success rate with CustomBone cranial prosthesis after 9,500+ implants
• +6 more outcomes

Named customers7 records

Segments7 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Rods&ConescoreTechnology or Integration · 1 February 2026New collaboration announced in February 2026 between Finceramica and Rods&Cones. Rods&Cones appears to be a technology company providing remote surgical assistance or visualization solutions that complement Finceramica's regenerative surgery products.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Zimmer Biomet: Zimmer Biomet offers bone graft substitutes, regenerative technologies, and joint reconstruction implants. It overlaps with Finceramica's orthopedic and osteochondral scaffold offerings as a broad incumbent.
• Smith+Nephew: Smith+Nephew has a regenerative medicine and orthobiologics franchise, including cartilage repair and bone graft products, making it a broad incumbent peer in adjacent sports medicine and orthopedic applications to Finceramica's MaioRegen.
• Baxter International: Baxter sells Actifuse bone graft substitute and a broader surgical solutions portfolio, competing with Finceramica's hydroxyapatite products in orthopedic and spinal fusion applications as a large incumbent with deeper sales coverage.
• Stryker: Stryker operates a large orthobiologics and extremities portfolio (including bone graft substitutes and regenerative solutions) and is a broad incumbent peer to Finceramica's orthopedic and spine bone regeneration products.
• Medtronic: Medtronic offers the Infuse bone graft (rhBMP-2) and a comprehensive spine and neurosurgery portfolio. It competes with Finceramica in spinal fusion, cranioplasty, and orthobiologics, with substantially greater commercial scale.

Emerging players

• Collagen Solutions: Collagen Solutions develops collagen-based biomaterials and tissue-engineered scaffolds for medical and dental applications, making it a smaller, emerging peer in the collagen-hydroxyapatite composite space overlapping with Finceramica's RegenOss.

Direct peers

• Geistlich Pharma: Geistlich manufactures Bio-Oss, the market-leading bovine bone graft substitute used in dental and orthopedic regeneration. It is a direct peer to Finceramica's ENGIpore and SINTlife in the bone graft substitute and orthobiologics category.
• Integra LifeSciences: Integra is a global regenerative medicine and neurosurgery device company with a dural repair and cranial reconstruction portfolio (e.g., DuraGen, custom cranial solutions) directly comparable to Finceramica's CustomBone cranial implant line.
• NovaBone Products: NovaBone manufactures synthetic calcium phosphate bioactive glass bone graft substitutes used in orthopedic, dental, and spine surgery. It is a direct peer to Finceramica's hydroxyapatite-based bone graft portfolio (ENGIpore, SINTlife).
• Biomatlante: Biomatlante develops synthetic calcium phosphate and hydroxyapatite bone substitutes (MBCP, In'Oss) for orthopedic, spine, and dental surgery. It is a direct peer to Finceramica's porous hydroxyapatite bone graft technology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/fin-ceramica-faenza-s-p-a-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Finceramica